Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OTLK Stock Forecast 2026-2027
$1.22
Current Price
$147.45M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to OTLK Price Targets
+391.8%
To High Target of $6.00
+391.8%
To Median Target of $6.00
-59.0%
To Low Target of $0.50
OTLK Price Momentum
+56.4%
1 Week Change
+430.4%
1 Month Change
-33.0%
1 Year Change
-22.8%
Year-to-Date Change
-64.0%
From 52W High of $3.39
+657.8%
From 52W Low of $0.16
📊 TOP ANALYST CALLS
Did OTLK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Outlook Therapeutics is one of their latest high-conviction picks.
Latest OTLK Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, OTLK has a neutral consensus with a median price target of $6.00 (ranging from $0.50 to $6.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.22, the median forecast implies a 391.8% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OTLK Analyst Ratings
2
Buy
2
Hold
0
Sell
OTLK Price Target Range
Low
$0.50
Average
$6.00
High
$6.00
Current: $1.22
Latest OTLK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OTLK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2026 | Ascendiant Capital | Edward Woo | Buy | Maintains | $10.00 |
| May 18, 2026 | BTIG | Julian Harrison | Neutral | Downgrade | $N/A |
| Mar 11, 2026 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Feb 18, 2026 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Feb 18, 2026 | Chardan Capital | Neutral | Maintains | $N/A | |
| Jan 5, 2026 | Chardan Capital | Neutral | Maintains | $N/A | |
| Jan 2, 2026 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Dec 22, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Sep 30, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Sep 22, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Aug 29, 2025 | Guggenheim | Neutral | Downgrade | $N/A | |
| Aug 29, 2025 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Aug 28, 2025 | Chardan Capital | Neutral | Maintains | $N/A | |
| Aug 15, 2025 | Chardan Capital | Neutral | Maintains | $N/A | |
| Jun 6, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Feb 24, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Feb 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 18, 2025 | Chardan Capital | Neutral | Maintains | $N/A | |
| Jan 17, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Jan 17, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Outlook Therapeutics Inc. (OTLK) Competitors
The following stocks are similar to Outlook Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Outlook Therapeutics Inc. (OTLK) Financial Data
Outlook Therapeutics Inc. has a market capitalization of $147.45M with a P/E ratio of 0.6x. The company generates $333,141 in trailing twelve-month revenue with a 4.0% profit margin.
Revenue growth is -110.6% quarter-over-quarter, while maintaining an operating margin of -11,006.8% and return on equity of +193.9%.
Valuation Metrics
Market Cap
$147.45M
Enterprise Value
$127.01M
P/E Ratio
0.6x
PEG Ratio
0.0x
Price/Sales
399.1x
Growth & Margins
Revenue Growth (YoY)
-110.6%
Gross Margin
-17.2%
Operating Margin
-11,006.8%
Net Margin
+4.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+5.2%
Current Ratio
0.5x
Debt/Equity
-0.9x
ROE
+193.9%
ROA
-184.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Outlook Therapeutics Inc. (OTLK) Business Model
About Outlook Therapeutics Inc.
What They Do
Develops ophthalmic treatments for retinal diseases.
Business Model
The company focuses on creating and commercializing ONS-5010/LYTENAVA, a specialized formulation of bevacizumab for treating retinal diseases, particularly wet AMD. Outlook Therapeutics generates revenue by targeting retina specialists and eye-care providers, offering a standardized and rigorously tested alternative to commonly used off-label treatments, thus addressing the needs for consistency and regulatory compliance in anti-VEGF therapies.
Additional Information
Headquartered in Iselin, New Jersey, Outlook Therapeutics is positioned within the biopharmaceutical sector, specifically targeting serious retinal disorders, which highlights its commitment to improving patient care and treatment options in ophthalmology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
23
CEO
Mr. Robert Charles Jahr
Country
United States
IPO Year
2016
Website
www.outlooktherapeutics.comOutlook Therapeutics Inc. (OTLK) Latest News & Analysis
Latest News
Quick Summary
Outlook Therapeutics received a buy rating after an FDA appeal victory, enhancing approval chances for Lytenava. Insider buying and shareholder support indicate confidence amid financial concerns.
Why It Matters
Outlook Therapeutics' FDA appeal win boosts Lytenava's approval chances, enhancing OTLK's value. Insider buying suggests confidence, despite financial risks, influencing investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Outlook Therapeutics has resubmitted its Biologics License Application to the FDA for ONS-5010/LYTENAVA™ to treat neovascular age-related macular degeneration.
Why It Matters
Outlook Therapeutics' BLA resubmission for ONS-5010 signals potential FDA approval, which could boost market confidence and share prices, impacting investor sentiment and future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Outlook Therapeutics, Inc. plans to sell 8.54 million shares at $0.5855 each to GMS Ventures, raising $5 million for working capital and corporate purposes, closing expected around May 29, 2026.
Why It Matters
Outlook Therapeutics' direct offering raises $5 million, indicating potential dilution for current shareholders. Usage of funds for working capital may impact growth and operational strategies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Outlook Therapeutics (NASDAQ: OTLK) shares rose after the FDA granted its appeal for ONS-5010 (LYTENAVA), following the Formal Dispute Resolution process.
Why It Matters
FDA approval of ONS-5010 boosts Outlook Therapeutics' prospects, potentially increasing revenue and market confidence, positively impacting share prices.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Outlook Therapeutics, Inc. announced the FDA granted their appeal regarding ONS-5010/LYTENAVA™ for retinal diseases after the Formal Dispute Resolution process.
Why It Matters
FDA approval of ONS-5010 enhances Outlook Therapeutics' prospects, potentially boosting revenue and stock value, impacting investor sentiment positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
29 days ago
Quick Summary
Outlook Therapeutics, Inc. (Nasdaq: OTLK) reported its Q2 fiscal 2026 results, ending March 31, focusing on improving bevacizumab treatment for retinal diseases.
Why It Matters
Outlook Therapeutics' Q2 financial results and corporate update can influence stock performance, indicating the company's growth potential and market position in retina disease treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About OTLK Stock
What is Outlook Therapeutics Inc.'s (OTLK) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Outlook Therapeutics Inc. (OTLK) has a median price target of $6.00. The highest price target is $6.00 and the lowest is $0.50.
Is OTLK stock a good investment in 2026?
According to current analyst ratings, OTLK has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OTLK stock?
Wall Street analysts predict OTLK stock could reach $6.00 in the next 12 months. This represents a 391.8% increase from the current price of $1.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Outlook Therapeutics Inc.'s business model?
The company focuses on creating and commercializing ONS-5010/LYTENAVA, a specialized formulation of bevacizumab for treating retinal diseases, particularly wet AMD. Outlook Therapeutics generates revenue by targeting retina specialists and eye-care providers, offering a standardized and rigorously tested alternative to commonly used off-label treatments, thus addressing the needs for consistency and regulatory compliance in anti-VEGF therapies.
What is the highest forecasted price for OTLK Outlook Therapeutics Inc.?
The highest price target for OTLK is $6.00 from at , which represents a 391.8% increase from the current price of $1.22.
What is the lowest forecasted price for OTLK Outlook Therapeutics Inc.?
The lowest price target for OTLK is $0.50 from at , which represents a -59.0% decrease from the current price of $1.22.
What is the overall OTLK consensus from analysts for Outlook Therapeutics Inc.?
The overall analyst consensus for OTLK is neutral. Out of 3 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are OTLK stock price projections?
Stock price projections, including those for Outlook Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 12:03 PM UTC